CN Patent

CN116171155B — 吡啶并[2,3-d]嘧啶-2(1H)-酮衍生物及其制备方法和应用

Assigned to Abbisko Therapeutics Co Ltd · Expires 2024-09-17 · 2y expired

What this patent protects

一种吡啶并[2,3‑d]嘧啶‑2(1H)‑酮衍生物及其制备方法和应用。所述衍生物用于制备治疗至少部分由K‑RAS G12C突变介导的癌症或肿瘤的药物，特别是治疗肺部、肝胆、胃肠道、血液系统、皮肤、骨、泌尿生殖道、神经系统、妇科性和肾上腺相关恶性肿瘤或癌症的药物，有望开发成新一代K‑RAS G12C抑制剂药物。

USPTO Abstract

一种吡啶并[2,3‑d]嘧啶‑2(1H)‑酮衍生物及其制备方法和应用。所述衍生物用于制备治疗至少部分由K‑RAS G12C突变介导的癌症或肿瘤的药物，特别是治疗肺部、肝胆、胃肠道、血液系统、皮肤、骨、泌尿生殖道、神经系统、妇科性和肾上腺相关恶性肿瘤或癌症的药物，有望开发成新一代K‑RAS G12C抑制剂药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN116171155B
Jurisdiction
CN
Classification
—
Expires
2024-09-17
Drug substance claim
No
Drug product claim
No
Assignee
Abbisko Therapeutics Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.